Kodiak Sciences shares more than doubled after Zenkuda and KSI-501 met their primary goal in a Phase 3 wet AMD study. The company plans to file for regulatory approval in Q4.
neutral 50 · impact 80
KOD announced Zenkuda and tabirafusp-ted met primary endpoints in Phase 3 DAYBREAK for wet AMD. Zenkuda now has five positive Phase 3 studies. BLA planned for 4Q26. KSI-101 data due December.
Kodiak Sciences shares surged 150% after its wet-AMD drugs Zenkuda and tabirafusp-ted met primary endpoints in the pivotal Phase 3 DAYBREAK trial. The company plans to file Zenkuda for approval in Q4, backed by five positive Phase 3 studies.
bullish 90 · impact 90
Zenkuda met the primary endpoint (p=0.0007) with 54% of patients on 6-month dosing. tabirafusp-ted also met endpoints. BLA submission planned for Q4 2026.
bullish 85 · impact 80
